+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06332885

Observational Study of Bronchoscopic Lung Volume Reduction Using Zephyr Endobronchial Valve in Severe Emphysema Patients Across Japan

Led by Pulmonx Corporation · Updated on 2026-09-17

140

Participants Needed

17

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are monitoring adults with severe emphysema who are candidates for bronchoscopic lung volume reduction using the Zephyr Endobronchial Valve. This observational study involves 140 patients across up to 20 centers in Japan and follows them for 12 months to evaluate the safety and effects of this treatment approach. Participants must have little to no collateral ventilation in the target lung lobe, confirmed by a specialized bronchoscopy assessment. Participants undergo a bronchoscopy with the Chartis system to check for collateral ventilation. Those confirmed suitable receive the Zephyr Valve placement in the most affected lung lobe. After the procedure, participants stay hospitalized for at least 3 nights for observation and then continue with follow-up visits for one year. A pulmonary rehabilitation program is also required between 45 days and 3 months after the valve placement. Throughout the study, lung function, exercise capacity, breathlessness, and quality of life are assessed at multiple time points. High-resolution CT scans are done at 45 days and 12 months to measure lung volume changes. Safety is monitored by tracking adverse events and the incidence of pneumothorax within 45 days after the procedure. This comprehensive follow-up helps researchers understand the treatments impact and safety profile over time.

CONDITIONS

Brief Title

Zephyr Valve Japan Post-Marketing Surveillance

Research Team

M

Marie Barrigar

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here